<DOC>
	<DOCNO>NCT00087698</DOCNO>
	<brief_summary>This study aim determine successful chemotherapy regimen Pemetrexed plus cisplatin surgery kill tumor none leave time surgery . Following surgery , eligible patient receive radiation chest . How patient respond , whether cancer return , , also monitor .</brief_summary>
	<brief_title>Phase II Trial Neo-Adjuvant Pemetrexed Plus Cisplatin Followed Surgery Radiation Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pleural Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients clinically stag use AJCC/UICC TNM stag criterion . Eligible stage : 1 . Patients must M0 2 . Patients T1 , T2 , T3 disease ( without cardiac involvement ) eligible ( T status establish clinically radiologically exploratory thoracotomy without surgical resection 3 . Patients N0 , N1 , N2 disease eligible Performance status 0 1 ECOG performance status schedule . No prior systemic chemotherapy prior intracavitary cytotoxic drug immunomodulators , unless give purpose chemical pleurodesis No previous radiation therapy Estimated life expectancy least 12 week Patients exclude meet ANY follow criterion : Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Have previously complete withdrawn study study investigate pemetrexed Pregnancy breastfeed Serious concomitant systemic disorder ( i.e . active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study Second active primary malignancy ( except situ carcinoma cervix , adequately treat nonmelanomatous carcinoma skin , low grade ( Gleason score less equal 6 ) , localize adenocarcinoma prostate malignancy treat least 2 year previously evidence recurrence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>